 Interleukin 1 Receptor Antagonist Protein
"Interleukin 1 Receptor Antagonist Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ligand that binds to but fails to activate the INTERLEUKIN 1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA.
| Descriptor ID |
D053590
|
| MeSH Number(s) |
D12.644.276.374.460 D12.776.467.374.460 D23.529.374.460
|
| Concept/Terms |
Interleukin 1 Receptor Antagonist Protein- Interleukin 1 Receptor Antagonist Protein
- Urine-Derived IL1 Inhibitor
- IL1 Inhibitor, Urine-Derived
- Urine Derived IL1 Inhibitor
- IL1 Febrile Inhibitor
- Febrile Inhibitor, IL1
- Interleukin 1 Inhibitor, Urine
- IL-1 Inhibitor, Urine
- IL 1 Inhibitor, Urine
- Urine IL-1 Inhibitor
- IL-1Ra
Antril- Antril
- Synergen Brand of Anakinra
- Anakinra Synergen Brand
Kineret- Kineret
- Amgen Brand of Anakinra
- Anakinra Amgen Brand
|
Below are MeSH descriptors whose meaning is more general than "Interleukin 1 Receptor Antagonist Protein".
Below are MeSH descriptors whose meaning is more specific than "Interleukin 1 Receptor Antagonist Protein".
This graph shows the total number of publications written about "Interleukin 1 Receptor Antagonist Protein" by people in this website by year, and whether "Interleukin 1 Receptor Antagonist Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin 1 Receptor Antagonist Protein" by people in Profiles.
-
Kakutani K, Yurube T, An HS, Doita M, Masuda K. Cytokine Inhibitors Upregulate Extracellular Matrix Anabolism of Human Intervertebral Discs under Alginate Beads and Alginate-Embedded Explant Cultures. Int J Mol Sci. 2023 Aug 02; 24(15).
-
Ghosh A, Rangasamy SB, Modi KK, Pahan K. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem. 2017 05; 141(3):423-435.
-
Smeekens SP, Gresnigt MS, Becker KL, Cheng SC, Netea SA, Jacobs L, Jansen T, van de Veerdonk FL, Williams DL, Joosten LA, Dinarello CA, Netea MG. An anti-inflammatory property of Candida albicans ?-glucan: Induction of high levels of interleukin-1 receptor antagonist via a Dectin-1/CR3 independent mechanism. Cytokine. 2015 Feb; 71(2):215-22.
-
Daly S, Rinewalt D, Fhied C, Basu S, Mahon B, Liptay MJ, Hong E, Chmielewski G, Yoder MA, Shah PN, Edell ES, Maldonado F, Bungum AO, Borgia JA. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol. 2013 Jan; 8(1):31-6.
-
Corbett GT, Roy A, Pahan K. Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defense. J Immunol. 2012 Jul 15; 189(2):1002-13.
-
Buvanendran A, Kroin JS. Does manipulating local surgical wound cytokines improve surgical outcomes? Anesth Analg. 2010 Dec; 111(6):1335-6.
-
Buvanendran A, Mitchell K, Kroin JS, Iadarola MJ. Cytokine gene expression after total hip arthroplasty: surgical site versus circulating neutrophil response. Anesth Analg. 2009 Sep; 109(3):959-64.
-
Opal SM, Fisher CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997 Jul; 25(7):1115-24.
-
Mundle SD, Venugopal P, Cartlidge JD, Pandav DV, Broady-Robinson L, Gezer S, Robin EL, Rifkin SR, Klein M, Alston DE, Hernandez BM, Rosi D, Alvi S, Shetty VT, Gregory SA, Raza A. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood. 1996 Oct 01; 88(7):2640-7.
-
Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994 Jun 15; 271(23):1836-43.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|